| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/08/2004 | US20040006780 VEGF-modulated genes and methods employing them |
| 01/08/2004 | US20040006245 For therapy of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain |
| 01/08/2004 | US20040006216 Comprises immunoglobulin for treating cancer; immunosuppressant; immunotherapy |
| 01/08/2004 | US20040006215 Human monoclonal antibodies against CD30 |
| 01/08/2004 | US20040006208 Comprises three-dimensional structure of bound immunoglobulin complex; antiinflammatory/anticarcinogenic; viricides |
| 01/08/2004 | US20040006205 Comprises g-protein coupled receptor polypeptides for diagnosis, prevention and treatment of cancers, infections and dyslipidemias |
| 01/08/2004 | US20040006134 Antiandrogenic biphenyls |
| 01/08/2004 | US20040006133 Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | US20040006123 Interleukin-4 gene expression inhibitors |
| 01/08/2004 | US20040006115 2-Oxothiazolidine 4-carboxylic acid compounds for promoting desquamation of the skin |
| 01/08/2004 | US20040006106 For therapy of breast cancer in mammals |
| 01/08/2004 | US20040006105 Thrombin receptor antagonists |
| 01/08/2004 | US20040006101 Quinolinone derivatives |
| 01/08/2004 | US20040006098 Induce cytokine biosynthesis in animals |
| 01/08/2004 | US20040006096 Substituted alkanohydroxamic acids and method of reducing TNFalpha levels |
| 01/08/2004 | US20040006095 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders |
| 01/08/2004 | US20040006089 For therapy of acromegalia, hypophyseal adenomas or endocrine gastroenteropancreatic tumors including carcinoid syndrome |
| 01/08/2004 | US20040006087 Method of treating cancer using FPT inhibitors and antineoplastic agents |
| 01/08/2004 | US20040006083 Pyrazolopyrimidines as therapeutic agents |
| 01/08/2004 | US20040006067 Substituted piperidines and methods of use |
| 01/08/2004 | US20040006060 Inducing contraception by delivering to a female of child-bearing age a selective estrogen receptor modulator comprising cyclothiocarbamate derivative |
| 01/08/2004 | US20040006058 As inhibitors of cyclin-dependent kinase 4 (Cdk4); antiproliferative agents; for therapy of cancer, tumors |
| 01/08/2004 | US20040006057 For therapy of connective tissue disorders, inflammatory disorders, immunology/allergy disorders, infectious diseases, respiratory diseases, cardiovascular diseases, eye diseases, metabolic diseases, central nervous system (CNS) disorders |
| 01/08/2004 | US20040006056 Substituted alkanoic acids |
| 01/08/2004 | US20040006051 Estrogen-linked platinum (II) complexes as anticancer agents |
| 01/08/2004 | US20040006049 For therapy of prostatitis, benign prostate hyperplasia or prostate cancer |
| 01/08/2004 | US20040006032 Vaccination |
| 01/08/2004 | US20040006023 Intravenous administration of a alpha -halogen- acryloyl distamycin derivative for therapy of tumors |
| 01/08/2004 | US20040006004 This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 |
| 01/08/2004 | US20040005693 Propagating and extracting reovirus from human embryonic kidney cells; ion exchange chromatography |
| 01/08/2004 | US20040005689 Three dimensional model of acute myeloid leukemia protein (AML-1) comprising runt domain for treating and preventing diseases associated with chromosomal translocations; genetic mapping |
| 01/08/2004 | US20040005688 Comprises dishevelled associated kinase (DAK) protein for diagnosis, prevention and treatment of cell proliferative diseases |
| 01/08/2004 | US20040005671 Immunointeractive molecules |
| 01/08/2004 | US20040005666 Methods and reagents for modulating cholesterol levels |
| 01/08/2004 | US20040005643 Anti-human tenascin monoclonal antibody |
| 01/08/2004 | US20040005629 Natural ligand of orphan G protein coupled receptor GPR86 and methods of use |
| 01/08/2004 | US20040005621 Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| 01/08/2004 | US20040005598 Comprises nucleotide sequences coding protein upregulated in metastatic prostate cancer (PUMPCn) for diagnosis and treatment of tumors; antiproliferative agents; anticarcinogenic agents |
| 01/08/2004 | US20040005581 Comprises nucleotide sequences coding vanilloid receptor-like receptor (VR4) for diagnosing and treating pain, inflammation, neurodegeneration, cardiovascular, cancer and urogenital diseases; drug screening |
| 01/08/2004 | US20040005576 Comprises polypeptides for diagnosing, prognosing and preventing cancer, nervous system, developmental and metabolic disorders |
| 01/08/2004 | US20040005561 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 01/08/2004 | US20040005550 Methods and compositions useful for targeting activated vitronectin receptor alphavbeta3 |
| 01/08/2004 | US20040005545 Plasmid comprising heterologous viral gene sequences for diagnosis, prevention and treatment of respiratory system disorders; vaccine development; viricides |
| 01/08/2004 | US20040005365 Carcinostatic substance for compatible administration, process of administrating same and process of rapidly inspecting same |
| 01/08/2004 | US20040005353 Delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is |
| 01/08/2004 | US20040005322 Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| 01/08/2004 | US20040005318 Method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided. |
| 01/08/2004 | US20040005313 Use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| 01/08/2004 | US20040005299 Method for producing pseudo islets |
| 01/08/2004 | US20040005298 Compositions and methods for restoring immune responsiveness in patients with immunological defects |
| 01/08/2004 | DE10228081A1 Verfahren zum Nachweis einer gesteigerten Tumorsuszeptibilität A method for detecting an increased tumor susceptibility |
| 01/08/2004 | DE10227269A1 Thiazolderivate Thiazole derivatives |
| 01/08/2004 | DE10226592A1 Tumorhemmende Platin(II)-oxalato-Komplexe Antitumor platinum (II) complexes -oxalato |
| 01/08/2004 | CA2513143A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| 01/08/2004 | CA2500165A1 Drug composition containing nf-.kappa.b inhibitor |
| 01/08/2004 | CA2493854A1 Phosphodiesterase inhibitor |
| 01/08/2004 | CA2493646A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | CA2492080A1 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 01/08/2004 | CA2492066A1 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | CA2492057A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 01/08/2004 | CA2491480A1 Humanized anti-lymphotoxin beta receptor antibodies |
| 01/08/2004 | CA2491427A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | CA2491363A1 Antibodies and uses thereof |
| 01/08/2004 | CA2491271A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 01/08/2004 | CA2491034A1 Methods and materials for treating human papillomavirus infections |
| 01/08/2004 | CA2490868A1 Method of up-regulating tumor antigen expression using thymalfasin |
| 01/08/2004 | CA2490811A1 Use of organic compounds |
| 01/08/2004 | CA2490692A1 Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
| 01/08/2004 | CA2490411A1 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | CA2490298A1 Porphyrin-polyamine conjugates for cancer therapy |
| 01/08/2004 | CA2490261A1 Differentiation modulating agents and uses therefor |
| 01/08/2004 | CA2490130A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor |
| 01/08/2004 | CA2490129A1 Compositions and methods comprising protein activated receptor antagonists |
| 01/08/2004 | CA2490017A1 Nucleic acid isolated from the 5' non translated region (5'ntr) end of the human fgf-1 gene having ires activity |
| 01/08/2004 | CA2490016A1 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 01/08/2004 | CA2489682A1 Method for the separation of triglycoalkaloids |
| 01/08/2004 | CA2489675A1 Glycoalkaloid compositions and various uses thereof |
| 01/08/2004 | CA2489560A1 Substituted quinoline ccr5 receptor antagonists |
| 01/08/2004 | CA2489555A1 Camptothecin-carboxylate formulations |
| 01/08/2004 | CA2489376A1 Methods of organ regeneration |
| 01/08/2004 | CA2488526A1 Stable liquid parenteral parecoxib formulation |
| 01/08/2004 | CA2487824A1 Oncolytic viruses as phenotyping agents for neoplasms |
| 01/08/2004 | CA2487712A1 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 01/07/2004 | EP1378573A1 Interleukin 1 beta protease and interleukin 1 beta protease inhibitors |
| 01/07/2004 | EP1378572A1 Bmp-11 compositions |
| 01/07/2004 | EP1378570A1 Flk-1 is a receptor for vascular endothelial growth factor |
| 01/07/2004 | EP1378525A2 Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods |
| 01/07/2004 | EP1378520A1 Cyclic single strand trispecific antibody |
| 01/07/2004 | EP1378512A1 Optically pure camptothecin analogues |
| 01/07/2004 | EP1378510A1 Triazaspiro 5.5]undecane derivatives and drugs containing the same as the active ingredient |
| 01/07/2004 | EP1378241A1 Pharmaceutical compositions comprising arsenic for the treatment of melanoma |
| 01/07/2004 | EP1378240A2 Pharmaceutical compositions comprising arsenic for the treatment of multiple myeloma |
| 01/07/2004 | EP1377680A2 Diagnosis and treatment of cancer: i |
| 01/07/2004 | EP1377676A2 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 01/07/2004 | EP1377672A2 Vector constructs |
| 01/07/2004 | EP1377671A2 Oncolytic adenoviral vectors |
| 01/07/2004 | EP1377667A2 Fusion proteins for specific treatment of cancer and auto-immune diseases |
| 01/07/2004 | EP1377609A2 Mhc molecule constructs and their uses for diagnosis and therapy |
| 01/07/2004 | EP1377607A2 Nucleic acid sequences of hyperplasies and tumors of the thyroid |
| 01/07/2004 | EP1377596A1 Ttk in diagnosis and as a therapeutic target in cancer |